On Apr. 16, 2020, CHF Solutions announced increased utilization of its Aquadex therapy in patients affected by COVID-19. Product sales of the Aquadex therapy to six hospitals in New York City, the epicenter of the pandemic in the U.S., have increased over 300% in the last thirty days, versus the 2019 monthly-average.

Aquadex therapy has been used as an alternative therapy in patients who need fluid removal when dialysis machines or trained dialysis personnel are not available and in hemodynamically unstable patients, who may not be able to tolerate dialysis but still need fluid removal.